Carlsmed reported Q4 revenue of USD 15.2 million, up 61.2% YoY, with gross margin of 76.5% and a net loss of USD 8.6 million. Q4 adjusted EBITDA was a loss of USD 8.4 million, while cash and cash equivalents, restricted cash and short-term investments totaled USD 109.9 million as of Dec. 31, 2025. For FY 2025, Carlsmed posted revenue of USD 50.5 million, up 86%, with gross margin of 75.3% and a net loss of USD 29.6 million; adjusted EBITDA was a loss of USD 28.4 million. The company guided FY 2026 revenue to USD 70 million to USD 75 million. Recent highlights included publication of 2-year lumbar outcome data in Global Spine Journal, the launch of the aprevo cervical system and the myaprevo ecosystem for browser and mobile integration, and February 2026 first-in-human procedures for an aprevo bi-lateral posterior fusion at the University of Colorado and a personalized corra cervical plating procedure at UC San Francisco. CEO Mike Cordonnier cited lead times reduced to within six business days and referenced published data showing a 74% reduction in revision rates at two years for aprevo lumbar patients versus non-aprevo patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251601PRIMZONEFULLFEED9661138) on February 25, 2026, and is solely responsible for the information contained therein.